Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris (Other)

Overall Status

Completed

CT.gov ID

NCT00006455

Collaborator

(none)

885

Enrollment

Locations

249.3

Actual Duration (Months)

88.5

Patients Per Site

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for treating anaplastic large cell lymphoma.

PURPOSE: This randomized phase III trial is studying several different regimens of combination chemotherapy to compare how well they work in treating children with anaplastic large cell lymphoma.

Condition or Disease	Intervention/Treatment	Phase
Lymphoma	Drug: cyclophosphamide Drug: cytarabine Drug: dexamethasone Drug: doxorubicin hydrochloride Drug: etoposide Drug: ifosfamide Drug: leucovorin calcium Drug: methotrexate Drug: therapeutic hydrocortisone Drug: vinblastine sulfate	Phase 3

Detailed Description

OBJECTIVES:

Compare the event-free survival in children with anaplastic large cell lymphoma treated with various induction and maintenance chemotherapy regimens with or without vinblastine.
Compare the impact of different doses and schedules of methotrexate from the Berlin-Frankfurt-Munster-K2 Protocol in terms of overall survival, complete remission rate, CNS relapse rate, and nonlymphoma-related death and early death rates in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to country, vinblastine (VBL) (yes vs no), and prognostic factors (standard-risk (SR) vs high-risk (HR) disease).

Beginning immediately after confirmation of diagnosis, patients receive prephase therapy comprising dexamethasone (DM) IV or orally daily on days 1 and 2 and every 12 hours on days 3-5; cyclophosphamide (CTX) IV over 1 hour on days 1 and 2; and methotrexate (MTX) intrathecally (IT), doxorubicin (DOX) IV, and hydrocortisone (HC) IT on day 1.

Patients are then assigned to one of two treatment groups based on prognosis:

Group 1 (SR disease): Patients are randomized to arm I or III:
Arm I: Patients receive treatment on arm I as defined below on day 1, and then the following courses as defined below in the following order beginning on day 6: A1, B1, A2, B2, A3, and B3.
Arm III: Patients receive treatment on arm III as defined below on day 1, and then the following courses as defined below in the following order beginning on day 6: regimen AM1, BM1, AM2, BM2, AM3, and BM3.
Group 2 (HR disease):
First randomization: Patients are randomized to arm I or III:
Arm I: Patients receive treatment on arm I as defined below on day 1 and then course A1 as defined below on day 6.
Arm III: Patients receive treatment on arm III as defined below on day 1 and then course AM1 as defined below on day 6.
Second randomization: Patients without disease progression after completion of the above therapy are randomized to arm I, II, III, or IV.
Arm I: Patients receive treatment on arm I as defined below on day 1, and then the following courses as defined below in the following order after blood counts recover: B1, A2, B2, A3, and B3.
Arm II: Patients receive treatment on arm II as defined below on day 1, and then the following courses as defined below in the following order after blood counts recover: BV1, AV2, BV2, AV3, and BV3.
Arm III: Patients receive treatment on arm III as defined below on day 1, and then the following courses as defined below in the following order after blood counts recover: BM1, AM2, BM2, AM3, and BM3.
Arm IV: Patients receive treatment on arm IV as defined below on day 1, and then the following courses as defined below in the following order after blood counts recover: BMV1, AMV2, BMV2, AMV3, and BMV3.

Patients are followed every 2 months for 1 year, every 4 months for 2 years, every 6 months for 2 years, and then annually thereafter.

DEFINITIONS:

Arms I-IV are defined below:
Arm I: Patients receive lower dose MTX IV over 24 hours and MTX IT.
Arm II: Patients receive lower dose MTX IV over 24 hours and MTX IT. Patients with HR disease also receive VBL IV weekly for 1 year beginning 3 weeks after initiation of course BV3.
Arm III: Patients receive higher dose MTX IV over 3 hours without intrathecal therapy.
Arm IV: Patients receive treatment as in arm III. Patients with HR disease also receive VBL IV weekly for 1 year beginning 3 weeks after initiation of course BMV3.
Regimens A, B, AV, BV, AM, BM, AMV, and BMV are defined below:
Regimen A (courses A1, A2, and A3): Patients receive DM IV or orally every 12 hours on days 1-5; MTX IV over 24 hours on day 1; MTX IT, DOX IV and HC IT (beginning 2-4 hours after initiation of MTX infusion) on day 1; leucovorin calcium (CF) IV rescue at 42, 48, and 54 hours after initiation of MTX infusion; ifosfamide (IFF) IV over 1 hour on days 1-5 (before initiation of MTX infusion); cytarabine (ARA-C) IV over 1 hour every 12 hours and etoposide (VP-16) IV over 2 hours once (beginning after completion of ARA-C infusion) on days 4 and 5. Each course lasts 3 weeks.
Regimen B (courses B1, B2, and B3): Patients receive DM, MTX, intrathecal therapy, and CF rescue as in regimen A. Patients also receive CTX IV over 1 hour on days 1-5 and DOX IV over 1 hour on days 4 and 5. Each course lasts 3 weeks.
Regimen AV (courses AV1, AV2, and AV3): Patients receive treatment as in regimen A and VBL IV on day 1. Each course lasts 3 weeks.
Regimen BV (courses BV1, BV2, and BV3): Patients receive treatment as in regimen B and VBL IV as in regimen AV. Each course lasts 3 weeks.
Regimen AM (courses AM1, AM2, and AM3): Patients receive DM IV or orally every 12 hours on days 1-5; MTX IV over 3 hours on day 1; and CF IV rescue every 6 hours for a total of 12 doses beginning 24 hours after initiation of MTX infusion. Patients also receive IFF, ARA-C, and VP-16 as in regimen A. Each course lasts 3 weeks.
Regimen BM (courses BM1, BM2, and BM3): Patients receive CTX and DOX as in regimen

Patients also receive DM, MTX, and CF rescue as in regimen AM. Each course lasts 3 weeks.

Regimen AMV (courses AMV1, AMV2, and AMV3): Patients receive treatment as in regimen AM and VBL as in regimen AV. Each course lasts 3 weeks.
Regimen BMV (courses BMV1, BMV2, and BMV3): Patients receive treatment as in regimen BM and VBL as in regimen AV. Each course lasts 3 weeks.

PROJECTED ACCRUAL: A total of 400 patients will be accrued for this study within 5.4-6.7 years.

Study Design

Study Type:

Interventional

Actual Enrollment :

885 participants

Allocation:

Randomized

Intervention Model:

Single Group Assignment

Primary Purpose:

Treatment

Official Title:

International Protocol for the Treatment of Childhood Anaplastic Large Cell Lymphoma

Actual Study Start Date :

Nov 26, 1999

Actual Primary Completion Date :

Jan 12, 2009

Actual Study Completion Date :

Sep 3, 2020

Outcome Measures

Primary Outcome Measures

Event-free survival []

Secondary Outcome Measures

Overall survival []
Complete remission achieved after treatment course B3 and lasting ≥ 4 weeks []
Short- and long-term toxicity []
Nonlymphoma related death and early deaths (excluding deaths occurring after second-line treatment for failure or relapse) []
CNS relapses []

Eligibility Criteria

Criteria

Ages Eligible for Study:

0 Years to 21 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

DISEASE CHARACTERISTICS:

Histologically proven standard-risk (SR) or high-risk (HR) anaplastic large cell lymphoma
SR disease defined by no involvement of the skin, mediastinum, liver, spleen, or lung
HR disease defined by any of the following:
Biopsy proven skin lesions (except skin lesions overlying an involved node or isolated skin disease)
Mediastinal involvement by x-ray or CT scan
Involvement of the liver (enlarged by at least 5 cm and/or nodular), spleen (enlarged and/or nodular), or lung (biopsy not needed for obvious lesions)
Histologic or cytologic slides must be available for national pathology review for all patients not meeting the classical criteria for diagnosis (typical histopathology, immunohistochemistry: CD30 positive, endomysial antibody positive, nucleophosmin negative, anaplastic lymphoma kinase (ALK) positive (if available), null or T-immunophenotype) unless proven t(2;5)
Must enroll within 1 week prior to beginning study regimen A
No CNS involvement (CSF or cerebral tumor)
First randomization (SR or HR disease):
Must have begun prephase therapy
No isolated primary skin disease
No low-risk disease defined as completely resected stage I disease
Second randomization (HR disease only):
Must have completed first randomization therapy without disease progression

PATIENT CHARACTERISTICS:

Age:

Under 22

Performance status:

Not specified

Life expectancy:

Not specified

Hematopoietic:

See Disease Characteristics

Hepatic:

See Disease Characteristics

Renal:

Not specified

Pulmonary:

See Disease Characteristics

Immunologic:

No congenital immunodeficiency
No AIDS

Other:

No prior malignancy

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

Not specified

Endocrine therapy:

Prior corticosteroids for anaplastic large cell lymphoma allowed if given for no more than 8 days

Radiotherapy:

Not specified

Surgery:

No prior organ transplantation

Other:

No other prior therapy for anaplastic large cell lymphoma

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	St. Anna Children's Hospital	Vienna		Austria	A-1090
2	U.Z. Gasthuisberg	Leuven		Belgium	B-3000
3	Institut Gustave Roussy	Villejuif		France	F-94805
4	Kinderklinik	Giessen		Germany	D-35385
5	Azienda Ospedaliera di Padova	Padova		Italy	35128
6	Dutch Childhood Leukemia Study Group	Den Haag		Netherlands	2504 AM
7	Hospital Clinico Universitario de Valencia	Valencia		Spain	46010
8	Karolinska University Hospital - Huddinge	Stockholm		Sweden	S-171 76
9	University Children's Hospital	Zurich		Switzerland	CH-8032
10	Addenbrooke's Hospital	Cambridge	England	United Kingdom	CB2 2QQ